• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: dbr:Tranilast     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatPhenolEthers, within Data Space : dbpedia.org associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAmidesyago:WikicatAnthranilicAcidsyago:WikicatBenzoicAcidsyago:WikicatMolecularFormulasyago:Abstraction100002137yago:Acid114607521yago:AliphaticCompound114601294yago:Alkene114713120yago:Amide114724264yago:BenzoicAcid114775321yago:CarboxylicAcid114739360yago:Chemical114806838yago:Communication100033020yago:Compound114818238yago:Element114840755yago:Formula106816935yago:Material114580897yago:Matter100020827yago:Message106598915yago:MolecularFormula106817173yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:Quintessence114847103yago:Relation100031921drugyago:Statement106722453yago:Substance100019613yago:WikicatAlkenesyago:WikicatPhenolEthers New Facet based on Instances of this Class

Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s.